About Dr. Qingqing Ding
I am a surgical pathologist with expertise in diagnosing all kinds of breast tumor. I have a broad background in basic and clinic cancer research, with specific training and expertise in tumor signaling transduction and tumor markers. My previous studies focused on the underling mechanisms of important clinical questions such as HER2-caused breast cancer chemoresistance, HBV-related hepatocellular carcinoma, colon cancer liver metastasis, Barrett’s esophagus-associated esophageal adenocarcinoma, et al. My current studies include translational and clinical studies in breast cancer such as sensitive and specific breast marker TRPS1, radiation-induced angiosarcoma, and molecular characters of malignant phyllodes tumor.
Present Title & Affiliation
Associate Professor, Department of Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
|2001||Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHN, PHD, Clinical Medicine|
|1995||Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHN, MD, Clinical Medicine|
|2015||American Board of Pathology|
Experience & Service
Section chief, autopsy, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - Present
Institutional Committee Activities
member, Faculty Academic Review Committee, 2018 - Present
Honors & Awards
|2021||The Shirley Stein Scientific Endowed Award, The University of Texas MD Anderson Cancer Center|
|2017||The Sheskey Family Fellowship award for Breast Cancer Research, The university of Texas MD Anderson Cancer Center|
|2016||The Bristol-Myers Squibb Award in Clinical Research, The university of Texas MD Anderson Cancer Center|
|2016||Breast pathology Mentioned Award, International Society of Breast Pathology|
|2009||Career Development Research Award, NCI-MDACC Breast Cancer SPORE|
|2001||Outstanding Doctoral Graduate Award, Tongji Medical College|
|1995||Outstanding Medical Graduate Award, Tongji Medical College|
- Shaker N, Shafi S, Parkinson B, Chen W, Parwani AV, Ding Q, Li Z. Wnt Family Member 9b (Wnt9b) Is a Sensitive and Specific Marker for Triple-negative Breast Carcinoma Including Metaplastic Carcinoma. Am J Surg Pathol 47(1):47-54, 2023. e-Pub 2022. PMID: 36525542.
- Cho WC, Nagarajan P, Ding Q, Prieto VG, Torres-Cabala CA. Trichorhinophalangeal Syndrome Type 1-Positive Cells in Breast Dermal Granulation Tissues and Scars: A Potential Diagnostic Pitfall. Am J Dermatopathol 44(12):964-967, 2022. e-Pub 2022. PMID: 35925150.
- Shafi S, Hu Y, Parwani AV, Ding Q, Li Z. Comprehensive analysis of clinicopathologic features and p53 mutation in neuroendocrine neoplasms of the breast: experience from a large academic center. Breast Cancer Res Treat 196(3):463-469, 2022. e-Pub 2022. PMID: 36260193.
- Zhan Y, Ding Q, Wu Z, et al.. The comparing investigation on the pDR2/TK gene injected the lobular blood vessels of the rat liver. Chinese Journal of Experimental Surgery 18(3):223-224, 2001.
- Ding Q, Wu Z, et al.. Gene Therapy of HSV-TK Tansferred by the EBV Based Expression Vector in the Experimental Hepatocellular Carcinoma . Journal of Tongji Medical University 21(2):122-125, 2001.
- Ding Q, Wu Z.. Progression of Stragery of Gene Therapy on Hepatocellular Carcinoma. Chinese Journal of Experimental Surgery 18(1):94-95, 2001.
- Ding Q, Wu Z.. Study of Targeting Gene Therapy on Hepatocellular Carcinoma. Foreign Medical Science (Fascicule of Surgery) 27(3):113-133, 2000.
- Ding Q, Qin X, Yuan Y, et al.. Clinicopathological Study on the Expression of p16 Protein in Thyroid Tumor. Chinese Journal of General Surgery 9(6):500-503, 2000.
- Yuan Y, Ding Q, Jiang H.,et al.. Bcl-2 and p53 Protein Expression and Apoptosis in Pancreatic Cancer. World Chinese Journal of Digestology 7(100):851-854, 1999.
- Ding Q, Qin X, et al.. Expression of bcl-2 and p53 Protein in Thyroid Tumor. Chinese Journal of Clinical Oncology 26(3):188-190, 1999.
- Ding Q, Tan J, Zhang L, et al.. Effect of Neferine on Isolated Billiary Smooth Muscales. Journal of Tongji Medical University 25(4):264-267, 1996.
Grant & Contract Support
|Title:||HER2 mutation in breast cancer|
|Funding Source:||MDACC Department of Pathology Seed Grant|
|Title:||TRPS1 is a novel biomarker for triple negative breast cancer|
|Funding Source:||MDACC Division of Pathology and Laboratory Medicine Research Award|
|Title:||Targeted treatment on breast cancer with concurrent HER2 and PIK3CA mutation|
|Funding Source:||MDACC Division of Pathology and Laboratory Medicine Supplemental Research Funds|
|Title:||Identifying molecular risk factor for post-radiation angiosarcoma of the breast|
|Funding Source:||MDACC Department of Pathology junior faculty grant|